42 results about "Anti angiogenesis" patented technology

A system for treating infantile hemangioma includes a first active substance delivery portion and a second active substance delivery portion. The first active substance delivery part delivers a first active substance to the superficial surface of the skin; the second active material delivery unit delivers a second active material to the deep part of the skin. The first active substance contains a beta receptor blocker, and the second active substance contains an antibiotic. Through verification, the beta receptor blocker and the antibiotic are delivered subcutaneously, and the effect of synergistically enhancing anti-angiogenesis and hardening promotion on infantile hemangioma is achieved.

The invention provides a recombinant collagen functional fragment. The amino acid sequence of the recombinant collagen functional fragment is as shown in SEQ ID NO. 2. The invention also provides a production method and application of the recombinant collagen functional fragment. The recombinant collagen functional fragment is formed by combining alpha 1 (IV) NC1 with the effects of inhibiting angiogenesis and tumor growth and HEPV with the effects of resisting tumors and stimulating expression of collagen IV and XVIIII alpha 1 chains, shows remarkable in-vitro anti-proliferative activity on various cancer cells, and is expected to have important application in the fields of angiogenesis resistance and tumor resistance.

A method of producing synergistic and enhanced efficacy in treating a disease in a subject includes providing an antibody, the antibody being a classic antibody or a modified biologic molecule that blocks a first target in the subject; providing a drug, the drug being a small molecule agent that blocks the first target or a second target in the subject; connecting the antibody and the drug with a linker to form an Antibody-Drug Synergism (ADS) compound; and treating the disease with the ADS compound. The linker is hydrolyzed in the subject over a certain time so that both the antibody and the drug exert their functions simultaneously, and the ADS compound confers better efficacy than either the antibody or the drug alone due to a synergism of the ADS compound.

An iRGD-LAMP2B-EGFP fusion protein mediated exosome surface engineering strategy is adopted, through specific recognition of iRGD peptide and integrin alpha v beta 3, corneal neovascularization core lesion cells are actively targeted, the limitation of off-target toxicity of a traditional delivery system is broken through, and a'accurate focus recognition-efficient homing 'targeted delivery normal form is established. Meanwhile, the screened circular RNA with anti-inflammatory and anti-angiogenesis dual activities is used as a core effector molecule, and in combination with an in-situ loading technology of the circular RNA molecule in an exosome parent cell, stable entrapment and targeted release of a nucleic acid drug in an exosome cavity are realized, and the problems that the nucleic acid drug is easy to degrade and poor in targeting property are solved; and dual guarantee of function specificity and delivery stability is formed. And a synergistic treatment system of a targeting exosome carrier and bifunctional circular RNA is further constructed, active molecules are accurately delivered to focus cells, and an inflammation microenvironment and an angiogenesis pathway are synchronously regulated and controlled.

The present invention is related to a C—X—C motif chemokine 12 (CXCL12) antagonist for use in a method for treating a tumor in a subject, wherein the method comprises administering to the subject—the C—X—C motif chemokine 12 (CXCL12) antagonist, —a radiotherapy, and—an anti-angiogenic compound, wherein the tumor is a brain tumor.

This invention belongs to the pharmaceutical field, specifically relating to an anti-tumor angiogenesis drug potentiator, an anti-tumor drug composition, and its application. Firstly, this invention discovers that SHCBP1 inhibitors can enhance the therapeutic effect of anti-tumor angiogenesis drugs and can be used as potentiators for anti-tumor angiogenesis drugs. Secondly, when SHCBP1 inhibitors are used in combination with anti-tumor angiogenesis drugs, or in combination with anti-tumor angiogenesis drugs and PD-1 inhibitors, tumor angiogenesis can be normalized and its window period prolonged, significantly improving the efficacy of immunotherapy, anti-angiogenesis, and anti-tumor therapy, showing broad application prospects.

Provided is an anti-neovascular therapy. More particularly, provided are anti-angiopoietin 2 (ANG2) antibodies or antigen binding fragments, which may be constructed as monospecific antibodies, or bispecific antibodies or fusion proteins (e.g., targeting human ANG2 and human serum albumin (HSA) ), or multifunctional fusion proteins, for example targeting ANG2, human vascular endothelial growth factor (VEGF), and HSA. In other aspects, methods for the production of these monospecific, bispecific, and multi-specific polypeptides, pharmaceutical compositions containing said antibodies and polypeptides, and uses thereof for treating neovascular disease are also provided.

The invention relates to application of IGFBP7 in clinical diagnosis of colorectal cancer and application of IGFBP7 as a drug target. The research shows that the expression quantity of IGFBP7 secreted by tumor endothelial cells is continuously reduced in the colorectal tumor formation process related to inflammation. Functional analysis proves that the endothelial-derived IGFBP7 is secreted into a tumor microenvironment and plays a role in resisting angiogenesis. In addition, the CRC cells can actively ingest the vesicles containing the IGFBP7. The IGFBP7 reduces the activity of a TGF-beta1 signal channel by inhibiting the expression of EGR1, thereby inhibiting the proliferation and migration of tumor cells. What is worthy of attention is that VAPA (Vesicle-associated Membrane Protein Associated Protein A) is identified to be a key factor for mediating IGFBP7 vesicles to be transferred to lysosome, and VAPA promotes the degradation of IGFBP7, so that the cancer suppression function of the IGFBP7 is weakened. The endothelial cell-derived IGFBP7 inhibits the progress of CRC (cyclic redundancy check) through an EGR1 / TGF-beta 1 pathway, and VAPA-mediated lysosome degradation limits the cancer inhibition effect of the endothelial cell-derived IGFBP7. The discovery emphasizes that the endothelial cell-derived IGFBP7 is a promising therapeutic target in the field of colorectal cancer.

The invention relates to structures and preparation methods of nine novel guaiane type sesquiterpene dimer compounds in xylostemma oblongifolium, and applications of the dimer compounds in anti-angiogenesis and anti-tumor aspects. The structures of the compounds are as shown in Figure 1. The invention also relates to a preparation method of the dimer compounds, and an application of the dimer compounds in anti-angiogenesis and anti-tumor aspects. The compound provided by the invention has angiogenesis inhibition activity and can be used for development and application of antitumor drugs.

The invention discloses application of niclosamide in preparation of a medicine for treating endometriosis, and belongs to the technical field of biological medicine. In-vivo and in-vitro experiments prove that the niclosamide can down-regulate the expression of primary endometriosis mesenchymal cells CD47 through a JAK / STAT3 pathway, enhance the phagocytosis of macrophages and play a role in effectively treating endometriosis; the invention provides the preparation method of the niclosamide microneedle, the preparation method is simple, the prepared LPHM-coated DDI NPs shows synergistic cytotoxicity and apoptosis induction activity in endometriosis mesenchymal cells, growth and recurrence of a focus of a subcutaneous endometriosis mouse model can be effectively inhibited through tumor ablation and anti-angiogenesis, and the niclosamide microneedle has a good application prospect. Rapid and effective treatment of endometriosis is realized in a microneedle patch mode.

This invention belongs to the field of DNA hydrogel technology, specifically relating to a VEGF-responsive, on-demand release smart DNA hydrogel of glycyrrhizin, its preparation method, and its applications. This invention constructs a VEGF-responsive smart DNA hydrogel, efficiently encapsulating glycyrrhizin within a three-dimensional gel network, utilizing the high expression of VEGF in the tumor microenvironment to trigger on-demand drug release. This invention achieves precise on-demand release of glycyrrhizin, significantly improving drug utilization efficiency and reducing systemic toxicity. Simultaneously, the VEGF aptamer introduced into the system can specifically bind to and neutralize free VEGF, blocking angiogenesis, cutting off tumor nutrient supply, and further inhibiting tumor proliferation and progression, achieving a synergistic effect of intelligent drug delivery and anti-angiogenesis.

The present invention belongs to the technical field of recombinant adeno-associated virus (rAAV) gene therapy, relates to the preparation of an rAAV-delivered Fc-engineered VEGF receptor fusion protein or an anti-VEGF antibody, and is applied to the treatment of angiogenesis-related fundus diseases, such as age-related macular degeneration, wet maculopathy, diabetic retinopathy and other diseases. Based on the aflibercept-expressing gene, the present invention uses recombinant AAV delivery to achieve long-term stable expression of a target gene in the RPE layer by means of genetic modification and vector optimization, thereby delivering an optimized target gene sequence to fundus cells of a patient.

The invention provides application of corydalis saxicola bunting in preparation of anti-angiogenesis drugs. The invention provides application of a corydalis saxicola bunting plant, a traditional Chinese medicinal material of the corydalis saxicola bunting plant or a corydalis saxicola bunting plant extract in preparation of anti-angiogenesis drugs. According to the present invention, the in vivo pharmacodynamic experiment performed by using the zebra fish angiogenesis model for the first time proves that the corydalis saxicola bunting extract can significantly inhibit the angiogenesis of zebra fish, such that the corydalis saxicola bunting extract has the anti-angiogenesis activity, and can be used as the angiogenesis inhibitor, the compound can be applied to treatment of neovascularization-dependent and neovascularization-related diseases such as tumors, arthritis, skin and ophthalmic diseases, atherosclerosis, vascular dementia, endometriosis and the like.

Pathogenic blood vessels are blood vessels that are not involved in the vascularization of normal organs but are in the pathogenic tissues such as the new blood vessels that drive vision diseases or the blood vessels in tumors that tumors depend on to survive. The current disclosure provides an advancement over typical anti-angiogenic strategies that target the generation of new blood vessels by providing compositions and methods that can selectively target and kill existing pathogenic blood vessels. The conventional antiangiogenic drugs or factors inhibit angiogenesis (the growth of new blood vessels), but cannot effectively kill existing pathogenic blood vessels. Agents, including small molecule compounds and antibodies, have been identified that bind to and activate PLXDC1 and PLXDC2 proteins, leading to effective killing of the endothelial cells in pathogenic blood vessels in vision diseases and in tumors that express these proteins. The disclosure thereby provides a novel modality for eliminating or reducing existing pathogenic blood vessels, thereby treating diseases such as diabetic retinopathy, age-related macular degeneration (AMD), retinopathy of prematurity, and cancer.

Provided is a nanoparticle or a pharmaceutical composition including the same for treating or remitting a neovascularization or an angiogenesis in eye segments, and the nanoparticle includes a hyaluronic acid and a therapeutic peptide. Also provided is a method for inhibiting formation or growth of blood vessels by administration of the nanoparticle or the pharmaceutical composition of the present disclosure to a subject in need thereof.

The invention provides an application of a PRC2 inhibitor compound in anti-angiogenesis, and an application of the PRC2 inhibitor compound in treating, alleviating and / or preventing non-tumor diseases related to anti-angiogenesis. The present invention relates to a use of a compound represented by formula (I), a pharmaceutically acceptable salt, a hydrate, a prodrug, a stereoisomer, a solvate or an isotope labeled compound thereof as a PRC2 inhibitor compound in the treatment, alleviation and / or prevention of non-tumor diseases including age-related macular degeneration and the like, in particular, a use of the compound represented by formula (I), the pharmaceutically acceptable salt, the hydrate, the prodrug, the stereoisomer, the solvate or the isotope labeled compound thereof as a PRC2 inhibitor compound.

The present application provides compounds / compositions, synthetic methods, methods of use. The compounds / compositions are directed to thyroid integrin antagonists conjugated to polymers. The compounds / compositions further include additional substituents that are also conjugated to the polymers. The compounds / compositions exhibit increased absorption across the blood brain barrier and increased retention therein and within tumors. The compounds / compositions can also include improved synthetic scalability, improved purity, improved water solubility, and solid products or intermediates. The compounds / compositions can exhibit improved anti-angiogenic effects, and improved efficacy against diseases, particularly cancers that require blood brain barrier permeability, such as malignant gliomas (GBM).

The application relates to the technical field of traditional Chinese medicine research, in particular to a screening method for quality markers of Aidi preparation. The method comprises the following steps: firstly, qualitatively analyzing chemical components, then quantitatively analyzing components with high content and capable of quantitative determination in traditional Chinese medicine; investigating the influence of light and temperature factors on the content of each component; according to the compatibility law of the monarch, minister, assistant and guide of the original medicinal materials in the compound, attributing the compounds; evaluating the anti-tumor and anti-angiogenesis activities of the candidate Q-markers and their respective synergistic activities of adriamycin in resisting tumor and anti-angiogenesis and reducing myocardial toxicity. Finally, a seven-dimensional spider web of “compatibility-content-stability-anti-tumor cell activity-synergistic DOX anti-tumor activity-anti-angiogenesis activity-synergistic DOX anti-angiogenesis activity” and a four-dimensional spider web of “compatibility-content-stability-reducing DOX cardiotoxicity” are established, and the Q-markers for resisting tumor and protecting heart toxicity of AD are comprehensively analyzed.

The invention relates to the technical field of biology, in particular to a PEDF mutant targeting VEGFR2 (vascular endothelial growth factor receptor 2) and application of the PEDF mutant in fundus neovascularization diseases. The sequence of the PEDF mutant of the targeted VEGFR2 is as shown in SEQ ID NO: 1. The invention provides a single injection recombinant adeno-associated virus (rAAV) gene therapy, which is used for treating VEGF (vascular endothelial growth factor) related eye diseases. The therapy prevents neovascularization by inducing expression of a mutant pigment epithelium-derived factor (PEDF). The method comprises the following steps: firstly, establishing two animal models of fundus neovascularization diseases, namely an extremely low density lipoprotein receptor gene knockout (Vldlr <- / ->) mouse model and an oxygen-induced ischemic retinopathy (OIR) mouse model; subsequently, anti-angiogenesis factors are injected into a vitreous cavity, and the result shows that clinically remarkable vasculopathy is almost completely inhibited in the established mouse fundus neovascularization model.

The present application relates to a kind of double antibody drug conjugate targeted to PD-L1 and VEGF and its preparation method and application.The general formula of the double antibody drug conjugate is Ab-(L-D) x;In general formula Ab, it is the double antibody targeted to PD-L1 and VEGF, includes PD-L1 antigen binding portion and VEGF antigen binding portion;In general formula L-D, it is connection unit-drug compound, L is connection unit, D is drug molecule, x is selected from the integer in 1~8.The double antibody drug conjugate includes PD-L1 antigen binding portion, VEGF antigen binding portion and drug molecule, and the synergistic efficacy between anti-angiogenesis, PD-L1 immune target and antibody conjugate is realized by reasonable structure design.

This application provides antibody-drug synergistic compounds, compositions, and methods for treating ocular diseases such as dry AMD, GA secondary to AMD, and exudative AMD. The antibody-drug synergistic compounds may include antibodies such as anti-angiogenic antibodies or anti-VEGF antibodies conjugated to small molecule complement inhibitors by a linker, or anti-complement antibodies conjugated to small molecule inhibitors of VEGF, VEGFR, PDGF, PDGFR, FGF, or FGFR by a linker. The linker conjugating the antibody and drug is hydrolyzable over time within the target eye, thereby allowing both the antibody and drug to exert their functions within the target eye. The compounds and compositions can confer superior efficacy compared to either the antibody or the drug alone due to the synergistic effect of the ADS compounds. Methods for treating age-related macular degeneration using ADS compounds and compositions are also provided.

The invention discloses application of a combination of a ferroptosis inducer and an anti-angiogenesis medicine in preparation of a medicine for treating tumors, the ferroptosis inducer is selected from one or more of Erastatin, RSL3, FIN56 and FIN02, the anti-angiogenesis medicine is DC101, and the tumors comprise one or more of melanoma, lung cancer, pancreatic cancer, gastric cancer, kidney cancer, colon cancer, breast cancer and liver cancer. Particularly, the ferroptosis inducer Erastatin and the anti-angiogenesis medicine DC101 are combined for use, and the use dosages of the ferroptosis inducer Erastatin and the anti-angiogenesis medicine DC101 are respectively 1-40 mg / kg and 1-20 mg / kg. The invention further provides a pharmaceutical composition containing the Erasttin and the DC101. The invention further provides the pharmaceutical composition containing the Erasttin and the DC101. The tumor treatment effect is improved by adopting a treatment mode of combining the ferroptosis inducer and the anti-angiogenesis medicine, the problem that the anti-angiogenesis treatment effect is poor is solved, the prognosis of tumor patients is improved, and the application has a wide clinical application prospect.

The present application provides antibody-drug synergistic compounds, compositions, and methods for treating ocular diseases, such as dry AMD, GA secondary to AMD, and exudative AMD. The antibody-drug synergistic compound may comprise an antibody such as an anti-angiogenic antibody or an anti-VEGF antibody linked to a small molecule complement inhibitor through a linking group; or an anti-complement antibody linked to a small molecule inhibitor of VEGF, VEGFR, PDGF, PDGFR, FGF or FGFR via a linking group. A linking group linking the antibody and the drug may hydrolyze in the eye of the subject over time such that both the antibody and the drug function in the eye of the subject. Due to the synergy of the ADS compounds, the compounds and compositions can confer better efficacy than the antibody or drug alone. Methods of treating age-related macular degeneration using the ADS compounds and compositions are also provided.

Provided is an anti-neovascular therapy. More particularly, provided are anti-angiopoietin 2 (ANG2) antibodies or antigen binding fragments, which may be constructed as monospecific antibodies, or bispecific antibodies or fusion proteins (e.g., targeting humanANG2 and human serum albumin (HSA) ), or multifunctional fusion proteins, for example targeting ANG2, human vascular endothelial growth factor (VEGF), and HSA. In other aspects, methods for the production of these monospecific, bispecific, and multi-specific polypeptides, pharmaceutical compositions containing said antibodies and polypeptides, and uses thereof for treating neovascular disease are also provided.

The invention belongs to the technical field of medicines, and discloses a liposome for resisting angiogenesis and down-regulating PD-L1 protein as well as a preparation method and application of the liposome. According to the invention, the active targeting liposome which is modified by NGR and is co-loaded with axitinib and siRNAPD-L1 is prepared by a film dispersion method and a lipid co-extrusion method. The method is simple in preparation process, low in cost, good in stability and high in repeatability. On one hand, Axi / siRNAPD-L1-coated NGR-Lipo inhibits tumor microangiogenesis, reshapes a tumor vascular system, normalizes tumor vessels, inhibits tumor metastasis and improves a tumor immunosuppression microenvironment; on the other hand, PD-L1 protein on the surfaces of tumor cells is silenced, tumor immune escape is relieved, and tumor immunotherapy is enhanced. The Axi / siRNAPD-L1 coated NGR-Lipo realizes an enhanced anti-tumor effect by combining an anti-angiogenesis therapy and an immune checkpoint blocking therapy. The preparation process of the liposome is simple and rapid, is easy for large-scale and industrial production, and also has a better development prospect in the aspect of clinical application transformation.

The application belongs to the technical field of microorganisms and novel food and medicine, and particularly relates to a novel polyene macrocyclic lactam compound and application thereof, and further discloses a method for preparing the polyene macrocyclic lactam compound based on a fermentation method. The polyene macrocyclic lactam compounds FW8-1 and FW8-4 both have polyene macrocyclic lactam structures, and due to the addition reaction in the molecule, the novel structure of intramolecular double ring is formed, which provides a compound reserve for researching and developing new potential anti-tumor, anti-inflammatory, anti-angiogenesis, anti-fibrosis, blood pressure regulation, immunoregulation and neuroprotective drugs.

The invention provides new materials and associated methods that are designed to address certain complex biological phenomena associated with pathologies such as cancer. In this context, embodiments of the invention disclosed herein can provide a multimodal, multitemporal approach to cancer therapy by, for example, targeting selected tumor vessels using materials designed deliver antineoplastic agents as well as anti-angiogenic agents, immunotherapeutic agents, and / or imaging agents, in a temporally controlled fashion.

The present invention belongs to the field of biomedicine and relates to an anti-angiogenic peptide, screening method, and application thereof. The anti-angiogenic peptide is polypeptide 1 or polypeptide 2; the amino acid sequence of polypeptide 1 is shown in SEQ ID NO. 1; polypeptide 2 is a polypeptide derived from polypeptide 1 by substitution, deletion, and / or addition of one or two amino acid residues and having the same glycosyltransferase function. The anti-angiogenic peptide provided by the present invention has good targeting and anti-angiogenic activity, and therefore has great practical application value.

An embodiment of the present application provides a stimulus-responsive multi-block copolypeptide comprising a peptide derived from pigment epithelium-derived factor (PEDF), a drug carrier, and a pharmaceutical composition thereof. The drug carrier can exhibit improved antiangiogenic activity by forming a multivalent nanostructure of which the size has been controlled through His-Zn2+ chelation.

The present application relates to the technical field of nanomedicine preparation, and particularly relates to a nanocarrier drug delivery system, a preparation method and application thereof. The nanocarrier drug delivery system comprises: extracellular vesicles loaded with methotrexate, lipid nanoparticles loaded with HIF-1 alpha shRNA plasmid, an outer carrier material and azobenzene; and the outer carrier material is modified with cell-penetrating peptide TAT-AT7. The transmembrane hypoxia-responsive hyaluronic acid nanocarrier drug delivery system prepared by the present application has good penetration and safety, is suitable for eye drop administration for treating ocular vascular proliferative diseases, has precise response drug release capacity for the hypoxic site of the lesion, target capacity for vascular endothelial cells and double treatment effects of synergistic anti-inflammatory and anti-angiogenic, and has a wide application prospect.